News and commentary from the endocrinology world
— News and commentary from the endocrinology world
July 28, 2026
• 2 min read
Major Pharmaceuticals issued a nationwide recall of multiple doses of levothyroxine sodium tablets, sold under the Major and Cardinal brands, due to subpotency. (USA Today)
The investigational triple agonist retatrutide met its primary endpoints of weight loss in the pivotal TRIUMPH-3 and TRIUMPH-2 trials of patients with severe obesity and either obesity or overweight plus type 2 diabetes, Eli Lilly announced.
A nationwide recall was issued for this common thyroid medication. See the recalled products.
Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically…
The FDA has recalled levothyroxine sodium nationwide due to potency standard concerns. This medication is used to treat…
News and commentary from the endocrinology world
Vitruvias Therapeutics, Inc. Issues Nationwide Recall of One Lot of Thyroid Tablets, USP 30 mg Due to Potential Super Potency
NEW YORK — GLP-1 receptor agonists offer dermatologic benefits but the same medications can leave patients grappling with several…
